[Blood cholesterol in patients with cancer]. / Colesterol sérico en pacientes neoplásicos.

In a retrospective, descriptive and observational study realized between 1995 and January 1997 the seric levels cholesterol of 610 patients with cancer and 61 healthy ones, who were used as controls were revised. The serum cholesterol observed in the patients with cancer were lower than the ones observed in the healthy controls. These differences show and statistical significance. We could see in our study that cholesterol were lower in patients with disseminate disease than in the ones with localize disease and that had and statistical value. The number of patients included in each type of tumor, the seric cholesterol were lower than the ones obtained in the control group apart from the patients with metastasis in and unknown origin tumor which have not been significant.

[The intralymphatic administration of adoptive immunotherapy (LAK) in the treatment of patients with metastatic cancer and resistant to conventional therapies. Apropos 50 patients]. / Administración intralinfática de inmunoterapia adoptiva (LAK) en el tratamiento de enfermos de cáncer metastásico y resistentes a las terapéuticas convencionales. A propósito de 50 enfermos.

Between January 1990 to December 1993, we administered LAK immunotherapy using intralymphatic route to 50 patients with metastatic cancer resistant to conventional therapies. In the preparations of the immunotherapy, followed the technique described by Pizza G. et al. The age of our patients ranged between 50 to 75 years and their Karnosfsky's indexes were above 70%. The histological type of the metastasis was determined by cytology and the size by Rx, ECO and/or TAC before and after the administration of the immunotherapy. In the intralymphatic administration, we followed the technique described by Pizza G. et al. The immunological therapy was administrated on days 1, 21, 90 and 111 and the clinical responses were assessed by RC, RP, SD and F. The immunological behaviour of the host was assessed through the determination of lymphoid populations (CD2, CD3, CD4, CD5 and CD8) and natural killer cells were studied with monoclonal antibodies CD3 and CD16. Such immunological study was carried out before the administration of each immunotherapy series. In 12 out of 50 patients (24%), we were able to administer the four LAK series. Such patients were subsequently studied, observing that although tumoral lesions did not increase in size, they did not disappear and, thus, they were classified as clinical stables. Clinical and analytical toxicity were null. The immunological study showed changes in immunological parameters, however these changes were not statistically significant.

[Intralymphatic administration of adoptive (LAK) immunotherapy in the treatment of patients with metastatic cancer resistant to conventional therapies]. / Administración intralinfática de inmunoterapia adoptiva (LAK) en el tratamiento de enfermos afectos de cáncer metastásico y resistentes a las terapéuticas convencionales.

Between January, 1990 and May, 1991, we administered LAK immunotherapy using the intralymphatic route to 25 patients with metastatic cancer resistant to conventional therapies. In the preparation of the immunotherapy, we followed the technique described by Pizza G. et al. The age of our patients ranged between 50 and 75 years and their Karnofsky's indexes were above 70%. The histological type of the metastasis were determined by Rx, ECO and/or CAT before and after the administration of the immunotherapy. In the intralymphatic administration, we followed the technique described by Pizza G. et al. The immunological therapy was administered on days 1, 21, 90 and 111 and the clinical response was assessed by RC, RP, EE and F. The immunological behaviour of the host was assessed through the determination of lymphoid populations (CD2, CD4, CD5 and CD8) and cytolytic cells were studied with monoclonal antibodies CD and CD16. Such immunological study was carried out before the administration of each immunotherapy series. In 7 out of 25 patients (28%), we were able to administer the four LAK series. Such patients were subsequently studied, observing that, although tumoral lesions did not increase in size, they did not disappear and, thus, they were classified as clinically stable. Clinical and analytical toxicity was null. The immunological study did not show any statistically significant changes and the activity of cytotoxic cells (NK) was not modified.

[Liver disease associated with hypernephroma. A case report (author's transl)]. / Hepatopatía asociada al hipernefroma. A propósito de un caso.

The observation of a non-metastatic reactive hepatopathy associated with a hypernephroma in a 39-year-old man who had had fever for 4 months led to a review of the literature and an analysis of basically three aspects of the disorder: a) The various manifestations of carcinoma of the kidney, which include a large number of paraneoplastic clinical symptoms (polycythemia, anemia, prolonged fever, hypercalcemia, hypertension, nefropathy, loss of salt, peripheral neuropathy, and amyloidosis); b) an alteracion of hepatic function known since 1961 which is characterized by an abnormal retention of sulfobromophthalein, increase of alkaline phosphatase, prothrombin decrease, dysproteinemia with hypoalbuminemia, and alpha2-globulin increase. It may or may not be accompanied by enlargement of the liver. c) Criteria of operability of the primary tumor.

Immunologic impairment in patients with non-lymphoid cancer: correlation with the tumoral stage, response to treatment and survival.

The cellular immunity has been studied in 121 patients by solid nonlymphoid tumors, and in 50 healthy patients, 11 with benign tumors, with the use of techniques of in vivo dinitrochlorobenzene (DNCB) and in vitro lymphocyte response to phytohemagglutinin to observe the correlation between both tests and the clinical stage of the disease, the response to chemotherapy and surgery, prognosis, and survival. Patients with anergy presented tumoral irresectability, lack of response to chemotherapy, advanced disease, and limited survival. In the patients with good immune response, the disease was limited, responding with greater frequency to therapy and presenting a higher rate of survival. Consequently, the immunologic study of a neoplastic patient can guide us toward a therapeutic behavior and a prognosis.